BRAF V600E — anti-EGFR resistance (colorectal)
Gene: BRAF · Type: mutation
Indications: Colorectal cancer
Evidence Level Distribution
Level A: 11Level B: 113Level C: 51Level D: 40Level E: 4
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Diagnostic | Supports | Positive | Papillary Thyroid Carcinoma | 5 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Dabrafenib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib,Dabrafenib | 5 |
| B | Prognostic | Does Not Support | Poor Outcome | Papillary Thyroid Carcinoma | 5 | |
| B | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 5 | |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 5 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Skin Melanoma | Vemurafenib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Skin Melanoma | Trametinib,Dabrafenib | 5 |
| B | Prognostic | Supports | Better Outcome | Colorectal Cancer | 5 | |
| A | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib,Cobimetinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Dabrafenib,Trametinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib,Dabrafenib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib,Dabrafenib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Dabrafenib,Trametinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Melanoma | Encorafenib,Binimetinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Encorafenib,Binimetinib,Cetuximab | 5 |
| A | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Encorafenib,Cetuximab | 5 |
| A | Predictive | Supports | Sensitivity/Response | Childhood Low-grade Glioma | Tovorafenib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Childhood Low-grade Glioma | Tovorafenib | 5 |